RxDoctor Payments Data

Orchid Mesias, NP

Nurse Practitioner · Mount Airy, MDNPI 1710627880

Payments from drug & device makers

$1,518in general payments, 2019–2025

Across 69 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$319
  • Collegium Pharmaceutical, Inc.$284
  • Medtronic$171
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$158
  • Novo Nordisk$121
  • Otsuka America Pharmaceutical, Inc.$101
  • plus $364 from 13 others

What the payments were for

  • Food & beverage$1,518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,518 in reported general payments places this provider in the 85th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$156,819
Medicare patients
343
Services billed
2,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate77$45,066
RelistorMethylnaltrexone Bromide17$37,709
BelbucaBuprenorphine Hcl50$36,849
Diclofenac Sodium59$19,881
OxycontinOxycodone Hcl36$18,633
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen423$12,523
Lidocaine83$10,583
MovantikNaloxegol Oxalate25$9,648
Fentanyl38$6,002
Hysingla ErHydrocodone Bitartrate14$5,498
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen174$5,022
Buprenorphine22$5,014
Morphine Sulfate ErMorphine Sulfate159$4,585
Oxycodone Hcl289$4,546
Tramadol Hcl ErTramadol Hcl62$3,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$284$81,915127 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$158$37,70917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Mount Airy

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →